Loading clinical trials...
Loading clinical trials...
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3 and AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3 or CNGA3
Conditions
Interventions
Prior exposure to AAV-CNGA3 or AAV-CNGB3
Locations
2
United States
Kellogg Eye Center
Ann Arbor, Michigan, United States
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom
Start Date
June 29, 2017
Primary Completion Date
April 4, 2024
Completion Date
April 4, 2024
Last Updated
June 11, 2025
Lead Sponsor
MeiraGTx UK II Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions